Milestone Hits Mark With RAPID Path To Potential Blockbuster Sales
The company plans to file for approval of etripamil in paroxysmal supraventricular tachycardia (PSVT) in mid-2023, with the drug having the possibility to reach sales of $1bn or more.
You may also be interested in...
Beam Therapeutics also announced that it dosed the first patient in its Phase I/II sickle cell disease trial; Vyne stepped into the increasingly competitive vitiligo space, while Tracon moved further into sarcomas in its checkpoint inhibitor program, and Telix started a small trial of its drug in brain cancer.
At nearly $194,000, the wholesale acquisition cost for Tzield came in above analysts’ $100,000-$115,000 estimates, but payer pushback is not expected as the drug faces no competition.
Data showed efficacy limited to IVS26-mutant Leber congenital amaurosis 10, which affects only 300 patients in the US. The company is pausing enrollment as it seeks a partner.